Jeffrey Glenn, MD, Professor, Department of Medicine and Microbiology & Immunology, Stanford University

Research Description: My interests lie in molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of novel anticancer and anti-NAFLD therapies. I am particularly interested in mechanisms to counter the development of resistance, such as by targeting host cell functions, or highly conserved essential RNA secondary structures via a process we term “programmable antivirals.” I work on a broad range of viruses, including enteroviruses, influenza, and coronavirus, and oversee and participate in the preclinical and early clinical evaluation of novel antiviral and anticancer therapies, as well as anti-MASLD agents. I have also successfully led productive academic-industry partnerships, and founded/ co-founded three biotechnology companies to advance the development of novel therapeutics (several currently in phase II-III). Together this experience and interest are ideally suited to the goals of the current proposal. I collaborate extensively with NORC member, Dr. Ahmed.